Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
5.59
-0.03 (-0.53%)
Jun 23, 2025, 4:00 PM - Market closed
Valneva SE Revenue
Valneva SE had revenue of 49.23M EUR in the quarter ending March 31, 2025, with 50.31% growth. This brings the company's revenue in the last twelve months to 186.06M, up 21.64% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
186.06M EUR
Revenue Growth
+21.64%
P/S Ratio
2.30
Revenue / Employee
260,950 EUR
Employees
713
Market Cap
463.24M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VALN News
- 14 days ago - UK's MHRA suspends Valneva's chikungunya vaccine for elderly - Reuters
- 18 days ago - Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 20 days ago - Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Valneva to Participate at U.S. and European Investor Conferences in June - GlobeNewsWire
- 6 weeks ago - Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States - GlobeNewsWire
- 6 weeks ago - Valneva SE (VALN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance - Seeking Alpha
- 6 weeks ago - Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly - GlobeNewsWire